13 studies were found.

1.		No longer recruiting	Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients Conditions: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Mixed Oligoastrocytoma; Malignant astrocytoma
2.		Recruiting	IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Oligoastrocytoma
3.		No longer recruiting	Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients with Recurrent Malignant Glioma Conditions: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Mixed Oligoastrocytoma
4.		Recruiting	Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma Conditions: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Mixed Oligoastrocytoma
5.		Recruiting	Liposome Encapsulated SN38 (LE-SN38) in Patients with Advanced Cancer Condition: Neoplasms
6.		Recruiting	Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients with Advanced Cancer Condition: Neoplasm
7.		No longer recruiting	Pre-operative IL13-PE38QQR in Patients with Recurrent or Progressive Malignant Glioma Conditions: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Mixed Oligoastrocytoma
8.		Recruiting	The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients with Recurrent Glioblastoma Multiforme Condition: Glioblastoma Multiforme
9.		Completed	Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients with Advanced Cancer Condition: Tumors
10.		Terminated	Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days Condition: Neoplasms
11.		Terminated	Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses Condition: Neoplasms
12.		No longer recruiting	Study to Determine Maximum Tolerated Dose of LErafAON Combined with Radiotherapy in Patients with Advanced Malignancies Condition: Neoplasms
13.		No longer recruiting	Study to Determine the Maximum Tolerated Dose of LErafAON in Patients with Advanced Solid Tumors Condition: Neoplasms